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We thank J. Peters * Elissa K. Deenick, 5, 6 Julie E. Niemela, 1 Danielle T. Avery, 5 Jean-Nicolas Schickel, 7 Dat Q. Tran, 8 Jennifer Stoddard, 1 Yu Zhang, 4, 9 David M. Frucht, 2 Bogdan Dumitriu, 10 Phillip Scheinberg, 10 Les R. Folio, 11 I mmune tolerance is controlled by multiple mechanisms (1, 2), including regulatory T (T reg ) cells (3) (4) (5) and inhibitory receptors (6, 7) . T reg cells constitutively express the inhibitory receptor CTLA-4, which confers suppressive functions (8, 9) . CTLA-4, also known as CD152, is also expressed by activated T cells and, upon ligation, inhibits their proliferation (10) . Homozygous deficiency of Ctla4 in mice causes fatal multiorgan lymphocytic infiltration and destruction (11-13); hence, CTLA-4 functions at a key "checkpoint" in immune tolerance. CTLA-4-immunoglobulin (Ig) fusion protein and neutralizing CTLA-4 antibody are used to modulate immunity in autoimmune and cancer patients (14, 15) , respectively. Studies have given conflicting results regarding the association of CTLA4 single-nucleotide variants (SNVs) with organ-specific autoimmunity (16) . The consequences of genetic CTLA-4 deficiency in humans are unknown.
Our index patient-a 22-year-old female (A.II.1)-developed brain, gastrointestinal (GI), and lung lymphocytic infiltrates, autoimmune thrombocytopenia, and hypogammaglobulinemia in early childhood ( Fig. 1A and + naïve cells, increased expression of the exhaustion marker PD-1, and a progressive loss of circulating mature B cells (Fig. 1B and table S1 ). Similar and overlapping immune phenotypes were detected in the additional families (Fig. 1, B to D, and table S1 ).
We performed whole-exome sequencing using DNA from A.II.1 and identified a heterozygous, nonsense c.151C>T (p.R51X) mutation in CTLA4. This was confirmed by Sanger sequencing in the proband and A.I.1 (Fig. 1C) . cDNA analyses from A.I.1 T cells showed that the mutant allele mRNA was degraded >95%, consistent with nonsensemediated decay (table S2) . CTLA4 sequencing in B.I.1 revealed a frameshift deletion (c.75delG; p.L28Ffs*44) (Fig. 1C) that introduced a stop codon in exon 2. Families C and D had mutations in introns 2 and 3 (458-1G>C and 567+5G>C) (Fig. 1C) disrupting the acceptor and donor sites of the second or third introns, respectively. These mutations generated a CTLA4 mRNA lacking the third exon, putatively encoding a soluble form of CTLA4 ( fig. S2A ). Full-length CTLA4 mRNA, encoding the membrane-bound form, was reduced. Serum-soluble CTLA-4 was comparable in patients and healthy individuals. In an extended cohort, de novo mutants were not identified; however, because B.I.1's parental genotypes are unknown, his mutation could be de novo.
Affected patients had reduced CTLA-4 protein and mRNA expression in sorted T reg cells relative to healthy donors; this reduction persisted after activation (Fig. 1D and fig. S2, A  and B) . Deletion of Ctla4 in mice impairs T reg cell suppressive function, causing severe autoimmune disease and early lethality despite normal Foxp3 levels (11, 12 - (Fig. 2, A and B) . activated autologous or allogeneic T responder cells (Fig. 2C and fig. S3D ). Among the nine subjects harboring CTLA4 mutations, three relatives were reportedly healthy (C.I.1, D.I.1, and D.II.2). Only one of these unaffected healthy relatives (D.I.1) could be evaluated in detail, and she had no clinical findings similar to CTLA-4-deficient patients. Her T reg cells showed higher expression of CTLA-4 and normal levels of FoxP3 and CD25 (fig. S4, A and  B) , whereas her effector T cells displayed the same in vitro hyperproliferation observed in affected patients (fig. S4C) ; these findings suggest that T reg cell dysfunction might be essential for the full disease phenotype.
Consistent with the results of studies in mice (11-13), CTLA-4-deficient patient T cells were hyperproliferative, with an increased percentage expressing CD25 in response to T cell receptor stimulation (Fig. 3A and fig. S5A ). To test whether patient T cell hyperproliferation resulted from reduced CTLA4 expression, we used small interfering RNA (siRNA) to inhibit CTLA4 expression in normal peripheral blood mononuclear cells (PBMCs). A factor of~3 reduction in CTLA4 recapitulated the hyperproliferative T cell phenotype (Fig. 3B) . Moreover, overexpression of wildtype CTLA-4 in patient T cells suppressed the hyperproliferation (Fig. 3C and fig. S5 , B and C), indicating that quantitative variations in CTLA-4 controlled the proliferative potential of T cells. CTLA-4-Ig fusion protein also suppressed patient T cell proliferation in vitro (Fig. 3D) . Despite hyperproliferation of patient T cells in culture, the patients were lymphopenic. This may be explained by increased FAS (CD95) expression, caspase activity, and apoptosis of patient T cells, or by organ sequestration ( fig. S6 ).
CTLA-4 function in B cells has been investigated, but its role remains unclear (8, 12, 19) . We found that CTLA-4 expression was significantly reduced on activated B cells from patients ( fig.  S7A ). The reduced frequencies of CD27 + classswitched memory B cells and progressive B cell lymphopenia (Fig. 4, A and B) , together with known B cell abnormalities in human autoimmune diseases (20) , prompted us to further investigate B cell maturation and function.
In inflammatory conditions such as systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome, CVID with autoimmunity and lymphoproliferation, and certain chronic infections, a population of B cells expressing reduced levels of CD21 (termed CD21 lo B cells) has been identified (21) (22) (23) . CD21 lo B cells have been viewed as anergic or "exhausted" cells on the basis of observations such as enrichment of self-reactive B cell receptors (BCRs), an activated phenotype, reduced responsiveness to BCR engagement, and increased apoptosis (22) (23) (24) (25) . We found that the frequency of CD21 lo B cells was greatly elevated in patients' peripheral blood ( S8A ) (21, 25 fig. S8B ). The propensity of CD21 lo B cells to exhibit more apoptosis ex vivo ( fig. S7C ) and their constitutive expression of CD95 ( fig. S8A ) could explain peripheral B cell lymphopenia and hypogammaglobulinemia in most CTLA-4-deficient patients. Increased frequencies of autoreactive mature naïve B cells have been demonstrated in the blood of patients with immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX), which is a primary T reg cell defect (26) ; this suggests a role for T reg cells in preventing the accumulation of autoreactive B cells in the periphery. Thus, CTLA-4 haploinsufficiency decreases B cell tolerance and survival either intrinsically or extrinsically because of T reg dysfunction (26) .
Our data indicate that germline CTLA4 haploinsufficiency causes lymphoproliferation, lymphocytic infiltration of nonlymphoid organs, autoimmune cytopenias, and B cell abnormalities with an accumulation of CD21 lo B cells. These cells may account for antibody-mediated autoimmunity in our patients. In contrast, heterozygous Ctla4 deficiency in mice shows no obvious phenotype (12, 13) . Interestingly, patient D.I.1, who has a CTLA4 splicing mutation with no apparent somatic reversions or leakiness, is clinically healthy (table S2) . This incomplete penetrance in disease may result from other genetic differences between family members. This is analogous to that in autoimmune lymphoproliferative syndrome, a human genetic immune disorder with only 60% penetrance among family members harboring the same heterozygous gene mutation (27) . Contrary to genetic deficiencies in inbred strains of mice, phenotypic variability is commonly observed in human single-gene disorders (28) . This may explain why D.I.1 has a CTLA4 mutation, yet is asymptomatic. C.I.1 and D.II.2 are apparently healthy because of incomplete penetrance; however, further immunological testing is required to confirm this assumption. We did not identify any common genetic modifiers in this study, as proven by our cohort analysis (see supplementary text). Also, our analysis of nonsynonymous SNVs in the CTLA4 coding region showed that CTLA-4 expression and T cell function are comparable to those of wildtype controls (table S3 and figs. S9 and S10). Nonetheless, our findings show that the mutations reported here result in quantitative reductions in CTLA-4 expression, which contribute to a severe loss of tolerance and infiltrative autoimmune disease.
Our results show the spectrum of clinical complications that can be anticipated from CTLA-4-blocking drugs. Consistent with these findings, treatment with the CTLA-4 mimetic, CTLA-4-Ig, suppressed patient T cell hyperproliferation in vitro (Fig. 3D ) and could be a potential therapeutic intervention for CTLA-4-deficient patients. Taken together, our results show that heterozygous CTLA4 mutations in humans are associated with a severe immunoregulatory disorder, which we term CTLA-4 haploinsufficiency with autoimmune infiltration (CHAI) disease.
